These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16940036)

  • 21. Exploratory Bayesian model selection for serial genetics data.
    Zhao JX; Foulkes AS; George EI
    Biometrics; 2005 Jun; 61(2):591-9. PubMed ID: 16011709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A semi-Markov model for multistate and interval-censored data with multiple terminal events. Application in renal transplantation.
    Foucher Y; Giral M; Soulillou JP; Daures JP
    Stat Med; 2007 Dec; 26(30):5381-93. PubMed ID: 17987670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.
    Canestri A; Ghosn J; Wirden M; Marguet F; Ktorza N; Boubezari I; Dominguez S; Bossi P; Caumes E; Calvez V; Katlama C
    Antivir Ther; 2006; 11(5):561-6. PubMed ID: 16964823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
    Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
    Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen.
    Hatano H; Hunt P; Weidler J; Coakley E; Hoh R; Liegler T; Martin JN; Deeks SG
    Clin Infect Dis; 2006 Nov; 43(10):1329-36. PubMed ID: 17051502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.
    Sahali S; Chaix ML; Delfraissy JF; Ghosn J
    AIDS Rev; 2008; 10(1):4-14. PubMed ID: 18385776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
    de Mendoza C; Garrido C; Corral A; Zahonero N; Soriano V
    AIDS; 2008 Jan; 22(2):311-3. PubMed ID: 18097236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal.
    Palma AC; Araújo F; Duque V; Borges F; Paixão MT; Camacho R;
    Infect Genet Evol; 2007 Jun; 7(3):391-8. PubMed ID: 17360244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
    Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
    J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The analysis of correlated panel data using a continuous-time Markov model.
    Lee EW; Kim MY
    Biometrics; 1998 Dec; 54(4):1638-44. PubMed ID: 9883555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.
    Benson CA; Vaida F; Havlir DV; Downey GF; Lederman MM; Gulick RM; Glesby MJ; Wantman M; Bixby CJ; Rinehart AR; Snyder S; Wang R; Patel S; Mellors JW;
    J Infect Dis; 2006 Nov; 194(9):1309-18. PubMed ID: 17041858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
    Deforche K; Cozzi-Lepri A; Theys K; Clotet B; Camacho RJ; Kjaer J; Van Laethem K; Phillips A; Moreau Y; Lundgren JD; Vandamme AM;
    Antivir Ther; 2008; 13(3):399-407. PubMed ID: 18572753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns among treatment-naive patients in different stages of infection in Rio de Janeiro, Brazil.
    Varella RB; Ferreira SB; de Castro MB; Zalis MG; Tavares MD
    J Med Virol; 2007 Aug; 79(8):1033-9. PubMed ID: 17596836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors.
    Geretti AM
    AIDS Rev; 2006; 8(4):210-20. PubMed ID: 17219736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inference for a linear regression model with an interval-censored covariate.
    Gómez G; Espinal A; W Lagakos S
    Stat Med; 2003 Feb; 22(3):409-25. PubMed ID: 12529872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A parametric survival model with an interval-censored covariate.
    Langohr K; Gómez G; Muga R
    Stat Med; 2004 Oct; 23(20):3159-75. PubMed ID: 15449329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
    Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
    J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey.
    Yerly S; von Wyl V; Ledergerber B; Böni J; Schüpbach J; Bürgisser P; Klimkait T; Rickenbach M; Kaiser L; Günthard HF; Perrin L;
    AIDS; 2007 Oct; 21(16):2223-9. PubMed ID: 18090050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.